Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Feb 2009

Gomes Erica M, Rodrigues Margret S, Phadke Anagha P, Butcher Lindsay D, Starling Cherry, Chen Salina, Chang Dongkun, Hernandez-Alcoceba Ruben, Newman Joseph T, Stone Marvin J, Tong Alex W

Abstract excerpt

PURPOSE: CD40 ligand (CD40L, CD154) plays a central role in immunoregulation and also directly modulates epithelial cell growth and differentiation. We previously showed that the CD40 receptor is commonly expressed in primary breast cancer tissues. In this proof-of-principle study, we examined the breast cancer growth-regulatory activities of an oncolytic adenoviral construct carrying the CD40L transgene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Adenovirus E1A Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to CD40 Ligand

Share to Genetic Therapy

Share to Mice, SCID

Share to Transgenes

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 19228733
DOI: 10.1158/1078-0432.CCR-08-1360

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells.PMID 19228733Read ↗

Prospect of Targeting the CD40 Pathway for Cancer TherapySemantic proximity Read ↗

Targeting phosphodiesterase 10A disrupts MAPK signaling pathways in the tumor microenvironment to unleash antitumor immunitySemantic proximity Read ↗

Spectrum-Wide Exploration of Human Adenoviruses for Breast Cancer TherapySemantic proximity Read ↗

Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer.Semantic proximity Read ↗

Immunogenetic therapy for B-cell malignancies.Semantic proximity Read ↗

Employing tumor hypoxia for oncolytic therapy in breast cancer.Semantic proximity Read ↗

Gene Immunotherapy of Chronic Lymphocytic Leukemia: A Phase I Study of Intranodally Injected Adenovirus Expressing a Chimeric CD154 MoleculeSemantic proximity Read ↗

Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.Semantic proximity Read ↗

Regression of Human Breast Carcinoma in Nude Mice After Ad <i>sflt</i> Gene Therapy is Mediated by Tumor Vascular Endothelial Cell ApoptosisSemantic proximity Read ↗

T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154.Semantic proximity Read ↗

Immunotherapeutic Potential of Anti-Human Endogenous Retrovirus-K Envelope Protein Antibodies in Targeting Breast TumorsSemantic proximity Read ↗

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in HumansSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.